High5

High5 is a biotechnology company developing a novel class of protein-based therapeutics known as "High5s." These molecules are engineered to be high-affinity, high-specificity, high-stability, high-solubility, and high-yield protein binders, designed to overcome the limitations of traditional antibodies and other protein scaffolds. Spun out from the VIB (Flanders Institute for Biotechnology) and Ghent University, the company utilizes its proprietary platform to create small, stable binders for various therapeutic and diagnostic applications. The High5 platform focuses on efficient microbial production, enabling cost-effective manufacturing and rapid development of new drug candidates.